The gut microbiome affects response of treatments in HER2-negative advanced gastric cancer.

ABSTRACT:

Background

Common treatments for metastatic/unresectable HER2-negative gastric cancer include chemotherapy, immune checkpoint inhibitor monotherapy and chemotherapy plus immune checkpoint inhibitor. However, significant drug resistance exists regardless of the treatment regimen.

Methods

Patients with metastatic/unresectable HER2-negative gastric/gastroesophageal junction adenocarcinoma were enrolled. All patients were divided into three groups according to the treatment regimen and were further divided into responders and non-responders according to efficacy evaluation. Metagenomics sequencing were performed to analyze gut microbiome signature of patients receiving different treatments at baseline and throughout treatment.

Results

One hundred seventeen patients with H

SUBMITTER: Han Z 

PROVIDER: S-EPMC10307992 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature